Olive leaf extract (Atherolive) for control of type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, placebo-controlled Phase 2/3 trial will enroll adults with type 2 diabetes at two emergency department exit points and two outpatient endocrinology/diabetology clinics in Monastir, Tunisia. Eligible participants will be assigned to receive either 400 mg Atherolive once daily or a matching placebo for three months. Baseline continuous glucose monitoring will be performed and laboratory panels (lipids, glucose, creatinine, HbA1c, and C-reactive protein) will be collected to track glycemic variability, metabolic measures, and inflammation. Outcomes will compare changes in glucose metrics, HbA1c, lipid profile, and inflammatory markers between the Atherolive and placebo groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients over 18 years of age with:
* diabetes.

Exclusion Criteria:

* Exclusion criteria: None.

Where it's running

• Semir Nouira
  Monastir, Monastir Tunisia, Tunisia Recruiting

Study contacts

• Principal investigator: Nouira Semir, Pr — University of Monastir
• Study coordinator: Nouira semir, Pr
• Email: semir.nouira@rns.tn
• Phone: 73106046

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proliverenol for liver fat and insulin resistance in type 2 diabetes

  This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.

  Recruiting Phase 2 Universitas Sriwijaya · Palembang, South Sumatera · NCT07928661

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes

  This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Neuss · NCT07896109

• RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes

  This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.

  Recruiting Bionime Corporation · Ulm, Baden-Wurttemberg · NCT07889388

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.